Large-scale outcomes trials of IL-6 inhibition that are currently ongoing include the HERMES trial (NCT05636176), a phase 3 study enrolling approximately 5600 patients with HFpEF or heart failure with mildly reduced ejection fraction and systemic inflammation, evaluating the effect of monthly ziltivekimab injections on clinical outcomes, such as cardiovascular death, hospitalization, and urgent heart failure visits. Here, IL6 is linked to heart failure.